What drove today’s move in IHL.AX stock?

Heavy trading followed corporate releases highlighting positive Phase 2 data and improved cash. Volume hit **61.36M**, raising liquidity and short-term volatility for IHL.AX stock.

How does Incannex’s balance sheet affect IHL.AX stock outlook?

Incannex reports over **A$70.00M** cash on hand in its U.S. release, supporting development through 2027. Strong cash reduces near-term dilution risk for IHL.AX stock.

What is Meyka AI’s view on IHL.AX stock?

Meyka AI rates IHL.AX **61.11/100 (B, HOLD)**. The grade balances clinical progress and cash against negative earnings and execution risk for IHL.AX stock.

What price targets should investors consider for IHL.AX stock?

Scenario targets: base **A$0.06**, bullish **A$0.18**, bearish **A$0.02**. Targets reflect trial outcomes, capital moves, and market re‑rating risk for IHL.AX stock.

AU Stocks

IHL.AX Incannex Healthcare ASX 15 Jan 2026: A$0.041 on 61.36M volume, clinical momentum

ByHuzaifa Zahoor January 15, 2026

IHL.AX stock closed the ASX session on 15 Jan 2026 at A$0.041, down 10.87% on exceptionally high turnover of 61.36M shares. We saw intraday trading between A$0.041 and A$0.051 as momentum rotated after the company’s recent U.S. corporate update. Investors are weighing a stronger cash position and positive Phase 2 data against steep year-to-date weakness and negative earnings. We summarise the drivers, valuation, and what to watch next for Incannex Healthcare Limited (IHL.AX) on the ASX in Australia.